THE BASIC PRINCIPLES OF TRASTUZUMAB BIOSIMILAR

The most below-investigated “driving forces” involved in trastuzumab resistance is PTEN. Nagata et al. (2004) claimed the lack of PTEN was noticed in 36% of HER2-favourable primary breast tumor specimens from sufferers with stage IV sickness. On top of that, they also confirmed that individuals with PTEN-deficient tumors experienced remarkably